Search results
Results from the WOW.Com Content Network
Clinical Trial to Determine Risk of Breast Cancer Recurrence (2005): This clinical trial is designed to select lymph node-negative, hormone receptor-positive breast cancers for chemotherapy treatment according to their risk of recurrence as measured by a test called OncotypeDx. One-time contract award in the amount of $4.5 million.
MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. [1] It gives a binary result, high-risk or low-risk classification , and helps physicians determine whether or not a patient will benefit from chemotherapy .
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...
breast cancer [9] CA27.29: breast cancer [10] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [11] CA-125: Mainly ovarian cancer, [12] but may also be elevated in for example endometrial cancer, fallopian tube cancer, lung cancer, breast cancer and gastrointestinal cancer. [13] Calcitonin
In cancer treatment, MRD testing has several important roles: determining whether treatment has eradicated the cancer or whether traces remain; monitoring patient remission status as well as detecting recurrence of cancer; comparing the efficacy of different treatments; helping patients and doctors make decisions [9] on whether to either
The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3] In cancer types with high survival ...
The Trial Early Serum Test Breast cancer (TESTBREAST) study includes 1,174 women in the Netherlands who are at a high risk of breast cancer, due to their family history or because they carry gene ...
A physical exam of the breast is one of the three tests that is scored that is a part of a triple test score. [12] A clinical breast examination (CBE) is different from a breast self-exam because a CBE is conducted by a physician during an appointment whereas a self-exam is recommend to be conducted monthly by patients at home.